These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 7081138)

  • 21. Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma.
    Bennouna J; Bompas E; Neidhardt EM; Rolland F; Philip I; Galéa C; Salot S; Saiagh S; Audrain M; Rimbert M; Lafaye-de Micheaux S; Tiollier J; Négrier S
    Cancer Immunol Immunother; 2008 Nov; 57(11):1599-609. PubMed ID: 18301889
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systemic therapy for renal cell carcinoma.
    Motzer RJ; Russo P
    J Urol; 2000 Feb; 163(2):408-17. PubMed ID: 10647643
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current status of the therapy of advanced renal carcinoma.
    Hrushesky WJ; Murphy GP
    J Surg Oncol; 1977; 9(3):277-88. PubMed ID: 327158
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Ovarian cancer: role of medical treatment].
    Cappelaere P; Chauvergne J; Guerrin J
    Bull Cancer; 1982; 69(3):284-91. PubMed ID: 7126897
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of renal carcinoma.
    Whitehead ED
    N Y State J Med; 1981 May; 81(6):911-4. PubMed ID: 6785679
    [No Abstract]   [Full Text] [Related]  

  • 26. Overview of interleukin-2 inhalation therapy.
    Huland E; Heinzer H; Huland H; Yung R
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S104-12. PubMed ID: 10685669
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytoreductive surgery in the management of metastatic renal cell carcinoma: the UCLA experience.
    Franklin JR; Figlin R; Rauch J; Gitlitz B; Belldegrun A
    Semin Urol Oncol; 1996 Nov; 14(4):230-6. PubMed ID: 8946623
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Immunology in clinical practice. XVII. Immunotherapy of metastatic renal cell carcinoma. Work Group Immunotherapy, Dutch Oncology].
    van Herpen CM; de Mulder PH
    Ned Tijdschr Geneeskd; 1998 Nov; 142(48):2613-8. PubMed ID: 10028361
    [TBL] [Abstract][Full Text] [Related]  

  • 29. No role of adjuvant systemic therapy after complete metastasectomy in metastatic renal cell carcinoma?
    Kwak C; Park YH; Jeong CW; Lee SE; Ku JH
    Urol Oncol; 2007; 25(4):310-6. PubMed ID: 17628297
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current immunotherapeutic strategies in renal cell carcinoma.
    Amato RJ
    Surg Oncol Clin N Am; 2007 Oct; 16(4):975-86, xi-xii. PubMed ID: 18022554
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current status of chemotherapy in the treatment of advanced carcinoma of the thyroid gland.
    Poster DS; Bruno S; Penta J; Pina K; Catane R
    Cancer Clin Trials; 1981; 4(3):301-7. PubMed ID: 7026075
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Therapy and prognosis of hypernephroid kidney carcinoma].
    Brühl P; Scheef W; Albert H; Bücheler E
    Med Klin; 1975 May; 70(20):873-8. PubMed ID: 805904
    [No Abstract]   [Full Text] [Related]  

  • 33. Carcinoma of the uterine cervix: current status and future directions.
    Thigpen T; Vance RB; Khansur T
    Semin Oncol; 1994 Apr; 21(2 Suppl 2):43-54; quiz 55, 58. PubMed ID: 8202720
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe.
    Negrier S; Maral J; Drevon M; Vinke J; Escudier B; Philip T
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S93-8. PubMed ID: 10685667
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Endocrinological effects of treatment with high doses of medroxyprogesterone acetate in patients with renal or prostatic adenocarcinoma.
    Tomic R; Ljungberg B; Damber JE
    Scand J Urol Nephrol Suppl; 1988; 110():185-7. PubMed ID: 2973122
    [No Abstract]   [Full Text] [Related]  

  • 36. Renal cell carcinoma: current status and emerging therapies.
    Nelson EC; Evans CP; Lara PN
    Cancer Treat Rev; 2007 May; 33(3):299-313. PubMed ID: 17329029
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel therapeutic strategies for treating esophageal adenocarcinoma: the potential of dendritic cell immunotherapy and combinatorial regimens.
    Milano F; Krishnadath KK
    Hum Immunol; 2008 Oct; 69(10):614-24. PubMed ID: 18703104
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized phase II study comparing thalidomide with medroxyprogesterone acetate in patients with metastatic renal cell carcinoma.
    Lee CP; Patel PM; Selby PJ; Hancock BW; Mak I; Pyle L; James MG; Beirne DA; Steeds S; A'Hern R; Gore ME; Eisen T
    J Clin Oncol; 2006 Feb; 24(6):898-903. PubMed ID: 16484699
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cytokine combinations: therapeutic use in patients with advanced renal cell carcinoma.
    Bukowski RM
    Semin Oncol; 2000 Apr; 27(2):204-12. PubMed ID: 10768599
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeted therapy for renal cell carcinoma: a new therapeutic paradigm.
    Shaheen PE; Bukowski RM
    Cancer Invest; 2006 Oct; 24(6):640-56. PubMed ID: 16982470
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.